Literature DB >> 9141375

Correlation between plasma homocyst(e)ine and aortic atherosclerosis.

N Konecky1, M R Malinow, P A Tunick, R S Freedberg, B P Rosenzweig, E S Katz, D L Hess, B Upson, B Leung, J Perez, I Kronzon.   

Abstract

Plasma homocyst(e)ine [H(e)] levels correlate with the prevalence of arterial occlusive diseases. Recently, transesophageal echocardiography (TEE) has been used to evaluate patients with atherosclerotic plaques in the thoracic aorta. The purpose of this study was to determine whether H(e) levels correlate with the degree of atherosclerotic plaque in the thoracic aorta (ATH) as seen on TEE. Maximum plaque areas for three locations in the thoracic aorta (arch, proximal descending, and distal descending) were measured with TEE in 156 patients. Maximum plaque areas for these locations were added to yield an estimate of ATH. ATH and H(e) levels, and levels of folic acid, vitamin B12, and pyridoxal 5'-phosphate were measured in a double-blind manner. Univariate analysis demonstrated a significant correlation of H(e) with ATH (r = 0.3, p< 0.001). On multivariate analysis, H(e) was independently predictive of ATH (r for the model including H(e) was 0.63, p < 0.0001). Plasma H(e) levels are therefore significantly and independently correlated with the degree of atherosclerosis in the thoracic aorta.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9141375     DOI: 10.1016/s0002-8703(97)70148-0

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  12 in total

1.  Cystathionine beta synthase gene dose dependent vascular remodeling in murine model of hyperhomocysteinemia.

Authors:  Neetu Tyagi; Natia Qipshidze; Utpal Sen; Walter Rodriguez; Alexander Ovechkin; Suresh C Tyagi
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2011-09-08

2.  Arterial embolism caused by large mobile aortic thrombus in the absence of atherosclerosis, associated with iron deficiency anemia.

Authors:  Inna F Bukharovich; Omar Wever-Pinzon; Ajay Shah; George Todd; Farooq A Chaudhry; Mark V Sherrid
Journal:  Echocardiography       Date:  2011-12-09       Impact factor: 1.724

Review 3.  Diagnosis and treatment of hyperhomocysteinemia.

Authors:  M E Keebler; C De Souza ; V Fonseca
Journal:  Curr Atheroscler Rep       Date:  2001-01       Impact factor: 5.113

Review 4.  Drugs affecting homocysteine metabolism: impact on cardiovascular risk.

Authors:  Cyrus Desouza; Mary Keebler; Dennis B McNamara; Vivian Fonseca
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 5.  Hyperhomocysteinemia and thrombosis.

Authors:  M Cattaneo
Journal:  Lipids       Date:  2001       Impact factor: 1.880

6.  Atherosclerotic disease of the proximal aorta and the risk of vascular events in a population-based cohort: the Aortic Plaques and Risk of Ischemic Stroke (APRIS) study.

Authors:  Cesare Russo; Zhezhen Jin; Tatjana Rundek; Shunichi Homma; Ralph L Sacco; Marco R Di Tullio
Journal:  Stroke       Date:  2009-06-04       Impact factor: 7.914

7.  Translational upregulation of folate receptors is mediated by homocysteine via RNA-heterogeneous nuclear ribonucleoprotein E1 interactions.

Authors:  Aśok Antony; Ying-Sheng Tang; Rehana A Khan; Mangatt P Biju; Xiangli Xiao; Qing-Jun Li; Xin-Lai Sun; Hiremagalur N Jayaram; Sally P Stabler
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

8.  Association of Dietary Factors with Progression of AA in Stroke/TIA Patients.

Authors:  Nishanth Kodumuri; Lauren Giamberardino; Alan Hinderliter; Souvik Sen
Journal:  J Neurol Disord       Date:  2016-06-30

Review 9.  Role of nitric oxide in matrix remodeling in diabetes and heart failure.

Authors:  Suresh C Tyagi; Melvin R Hayden
Journal:  Heart Fail Rev       Date:  2003-01       Impact factor: 4.214

Review 10.  Atherogenesis: hyperhomocysteinemia interactions with LDL, macrophage function, paraoxonase 1, and exercise.

Authors:  Ilya Chernyavskiy; Sudhakar Veeranki; Utpal Sen; Suresh C Tyagi
Journal:  Ann N Y Acad Sci       Date:  2016-02-05       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.